Ambroxol tablets 30mg №10×5

Name Ambroxol tabl. Expectorants, excluding combinations with antitussives. Indications for use Secrolytic therapy for acute and chronic bronchopulmonary diseases, accompanied by impaired formation and excretion of bronchial secretions (sputum). Dosage and administrationAdults and adolescents over 12 years of age: During the first 2-3 days, 3 times a day, 1 tablet (equivalent to 3 times 30 mg of ambroxol hydrochloride / day), then 2 times a day, 1 tablet (equivalent to 2 times a day). 30 mg ambroxol hydrochloride / day) If necessary, to increase efficiency – 2 tablets 2 times a day (equivalent to 120 mg ambroxol hydrochloride / day). The duration of use is determined by the doctor individually. The duration of use without consulting a doctor is no more than 4-5 days. Patients with impaired liver function Patients with impaired liver function do not require dose adjustment. Patients with renal insufficiency In case of impaired renal function, Ambroxol can be taken only after consulting a doctor. Elderly patients Elderly patients do not require dose adjustment. Missed dose If you forget to take Ambroxol or take an insufficient amount, continue taking the drug further according to the dosing regimen. Ambroxol is taken orally with a small amount of water. The drug can be taken regardless of food intake. Use during pregnancy and lactation Ambroxol crosses the placental barrier. The safety of the drug during pregnancy has not been established. The use of Ambroxol during pregnancy is not recommended, especially in the first trimester. Ambroxol is excreted in breast milk. The safety of the drug during lactation has not been established. Ambroxol is not recommended for use during breastfeeding. The effect of the drug on the ability to drive a car and use mechanisms There are no data confirming the effect of ambroxol on the ability to drive a car and work with mechanisms. Studies of the effect of the drug on the ability to drive a car and work with mechanisms have not been conducted. Precautions Do not combine with antitussives that make it difficult to remove sputum. One tablet of Ambroxol contains 147 mg of lactose monohydrate, which is 588 mg of lactose monohydrate in the maximum recommended daily dose (120 mg). This drug should not be taken by patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or poor glucose-galactose absorption. There have been reports of the development of severe skin reactions such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis in patients taking ambroxol. These cases can be explained, as a rule, by the severity of the concomitant disease or the simultaneous use of other drugs. In addition, in the early stages of Stevens-Johnson syndrome and toxic epidermal necrolysis, patients may show signs of the onset of a nonspecific influenza-like illness: fever, body pain, rhinitis, cough, and sore throat. The appearance of these signs can lead to unnecessary symptomatic treatment with cold medicines. It is necessary to immediately stop taking the drug if symptoms of a progressive skin reaction (sometimes associated with the development of blisters and lesions of the mucous membranes) appear. In case of impaired renal function or severe liver disease, Ambroxol can be taken only after consulting a doctor. As with other drugs that are metabolized in the liver and then excreted by the kidneys, in the presence of severe renal insufficiency, the accumulation of ambroxol metabolites in the liver is possible. Use with caution in diseases accompanied by impaired bronchial motility and the formation of a large amount of secretion (for example, a rare malignant Kartagener’s syndrome – primary celiar dyskinesia) due to possible blockage of the bronchial secretions. Interaction with other drugs Compatible with drugs that inhibit labor activity. Combined use with antitussive drugs leads to difficulty in sputum discharge against the background of a decrease in cough and a dangerous accumulation of exudate, therefore, simultaneous use is possible only after a thorough assessment of the benefits and risks. Increases the penetration and concentration in the bronchial secretion of amoxicillin, cefuroxime and erythromycin. Contraindications Hypersensitivity to ambroxol or other components of the drug. Pregnancy and lactation. Rare hereditary intolerance to any of the auxiliary components of the drug (see section “Precautions and features of use”). Composition Each tablet contains: active substance: ambroxol hydrochloride – 30 mg; excipients: lactose monohydrate, microcrystalline cellulose, corn starch, magnesium stearate, anhydrous colloidal silicon dioxide. Overdose Symptoms of overdose in humans are not described. In case of accidental overdoses and/or cases of medical error, the observed symptoms have been reported to be consistent with the known side effects of ambroxol when taken at the recommended doses. Possible: nausea, vomiting, diarrhea, dyspepsia. Treatment: artificial vomiting, gastric lavage in the first 1-2 hours after taking the drug; intake of fat-containing products, symptomatic therapy. Side effect The frequency of adverse reactions indicated below was determined using the following classification: very often (? 1/10), often (? 1/100 – < 1/10), infrequently (? 1/1.000 - < 1/100), rarely (? 1/10.000 - < 1/1.000), very rare (< 1/10.000), not known (cannot be determined from the available data). Respiratory, chest and mediastinal disorders: very rarely - rhinorrhea, dry airways; unknown - shortness of breath. Gastrointestinal disorders: often - diarrhea; infrequently - gastrointestinal disorders (nausea, vomiting, dyspepsia and abdominal pain); rarely - heartburn; very rarely - constipation, salivation. Immune system disorders: rarely - hypersensitivity reactions; the frequency is unknown - anaphylactic reactions, including anaphylactic shock, angioedema, itching. Skin and subcutaneous tissue disorders: rarely - rash, urticaria; frequency unknown - severe skin reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis). Renal and urinary tract disorders: very rarely - dysuria. General disorders: infrequently - fever, reactions from the mucous membranes. If the listed adverse reactions occur, as well as if an adverse reaction occurs that is not mentioned in the instructions, you should consult a doctor. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Buy Ambroxol tablets 30mg No. 10x5 Price for Ambroxol tablets 30mg No. 10x5